ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1839

Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE

Lena Eder1, Megan Clowse2, Amanda Eudy3, Jennifer Rogers4, Rebecca Sadun3, Lisa Criscione-Schreiber5, Jayanth Doss3, Mithu Maheswaranathan6, Amy Corneli7, Hayden Bosworth6 and Kai Sun6, 1Duke University Hospital, Chapel Hill, NC, 2Duke University, Chapel Hill, NC, 3Duke University, Durham, NC, 4Duke University Hospital, Durham, DE, 5Division of Rheumatology and Clinical Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, 6Duke University Hospital, Durham, 7Duke University, Durham

Meeting: ACR Convergence 2020

Keywords: Access to care, Minority Health, Qualitative Research, quality of care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Treatment Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Medication non-adherence in SLE is as high as 80%, yet little is known about adherence barriers faced by patients or interventions that improve adherence in SLE. We developed an intervention based on our prior study results in collaboration with lupus clinic stakeholders and pilot-tested it in a tertiary care lupus clinic. As part of the intervention, providers shared objective pharmacy refill data with patients during the encounter to elicit adherence barriers and discussed approaches to overcoming barriers. These were then documented in the clinic note via a dropdown menu with multiple choice options (Table 1). Here we describe adherence barriers elicited and approaches suggested to overcome them as noted by lupus providers during this pilot intervention.

Methods: We conducted the pilot intervention during regular clinic visits over 12 weeks on consecutive follow-up SLE patients who were prescribed ≥1 SLE medication. Adherence was assessed by medication possession ration (MPR) based on Surescripts refill data available in the EMR supplemented by phone calls to patients’ pharmacies. Adherence was assessed for the 3-month periods before and after the intervention visit, using MPR ≥80% as a cutoff for being adherent. Approaches to overcome barriers documented by providers were collected via chart review.

Results: Among 134 SLE patients seen during the intervention period, 70 (median age 40, 96% female, 66% African-American) were inconsistent at refilling at least one SLE medication (MPR < 80%). Lupus clinic providers identified and documented adherence barriers for 39 (56%) of the 70 patients with low refills. The most common barriers were busyness or forgetting (51%), cost or insurance issues (28%), side effects (15%), pill burden (8%), and lack of motivation (8%). Three months following the intervention visit, 33 (47%) of 70 patients with low refill rates now are considered adherent. There was no significant difference in the distribution of barriers between those with and without improved adherence after the intervention visit. Approaches to overcoming barriers documented by providers included: strategies to help with remembering, for example, using a reminder, app, or pill box, moving pills to a more visible area, or involving a family member to remind the patient (n=10); modifying the medication schedule or prescription (n=7); eliciting help from the pharmacist and/or social worker for cost and insurance issues (n=5); providing education or clearer instructions (n=5); treating side effects (n=2); and addressing depression (n=1).

Conclusion: We found that the most frequent medication adherence barriers faced by SLE patients related to the logistics of taking medications, financial burden, and side effects. The most common approach to address barriers suggested by providers were strategies to help with logistics of taking medications. The similar distribution of adherence barriers between those who did and did not have improved adherence after the intervention visit suggests that most of the barriers are modifiable.


Disclosure: L. Eder, None; M. Clowse, UCB, 5, GSK, 2, 5, Astra Zeneca, 5, Pfizer, 2; A. Eudy, NIH NCATS Award Number 1KL2TR002554, 2, Pfizer, 2; J. Rogers, None; R. Sadun, None; L. Criscione-Schreiber, None; J. Doss, None; M. Maheswaranathan, None; A. Corneli, None; H. Bosworth, None; K. Sun, None.

To cite this abstract in AMA style:

Eder L, Clowse M, Eudy A, Rogers J, Sadun R, Criscione-Schreiber L, Doss J, Maheswaranathan M, Corneli A, Bosworth H, Sun K. Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/medication-adherence-barriers-and-opportunities-to-overcome-them-among-patients-with-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medication-adherence-barriers-and-opportunities-to-overcome-them-among-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology